指南与共识骨软组织肉瘤与黑色素瘤

肉瘤诊断与治疗中下一代测序应用指南:共识综述

Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
指南 / 共识 · JAMA Oncol · 2025-01-01

该共识综述指出,肉瘤突变负荷低,NGS在肉瘤诊疗中的常规非选择性应用证据有限。诊断上不推荐对所有疑似肉瘤病例 upfront 使用NGS融合panel,治疗上常规NGS因可靶向变异少且匹配治疗临床获益证据有限而不被支持。NGS检测决策及结果解读应在肉瘤专家机构内多学科进行。

要点

  • 不推荐对所有新发疑似肉瘤病例常规 upfront 使用NGS融合panel。
  • 常规NGS治疗选择证据不足,靶向治疗主要基于特定亚型而非NGS结果。
  • NGS检测及结果解读应在肉瘤专家机构内多学科Review。

核心结论

  • 当前支持肉瘤患者常规、非选择性使用NGS的证据有限。
  • NGS检测决策及结果用于诊断或治疗目的应在肉瘤专家机构内多学科进行。
  • 非专家肉瘤中心的多基因panel结果不能替代病理复核或NGS指导治疗推荐。

研究设计与样本

  • 共识综述,由共识专家组基于文献与临床经验形成推荐。

主要发现

  • 肉瘤突变负荷极低,部分为基因组简单型(由复发性遗传改变驱动),部分为基因组复杂型(广泛基因组重排)。
  • 缺乏前瞻性研究比较对所有新发疑似肉瘤病例 upfront 使用NGS融合panel与仅由肉瘤专家病理学家评估指示使用的策略。
  • 相当比例肉瘤携带特定分子改变,但多数亚型具有经典组织学特征,并非所有病例需NGS确诊。
  • 当前证据不支持对所有肉瘤患者常规临床使用NGS,因可靶向改变少且NGS匹配治疗临床获益证据有限。

临床怎么用

  • NGS panel检测应在肉瘤专家机构内、经多学科讨论后决定。
  • 靶向药物选择主要基于特定肉瘤亚型,准确诊断不可或缺。
  • 非专家中心的多基因panel结果需经肉瘤专家评估后方可用于临床决策。

局限性

  • 缺乏前瞻性研究比较NGS upfront 使用与病理专家指示使用的策略。
  • NGS匹配治疗的临床获益证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple (driven by recurrent genetic alterations) and genomically complex (characterized by extensive genomic rearrangements) subtypes. Regardless, sarcomas exhibit a remarkably low mutational burden. In this context, there is a growing demand for the use of next-generation sequencing (NGS)-based technologies to aid in the clinical management of patients with sarcoma. However, a broad, clinically impactful implementation faces inherent challenges associated with their rarity, heterogeneity, and limited molecular understanding. OBSERVATIONS: From a diagnostic standpoint, there is a lack of prospective studies comparing up-front, indiscriminate use of NGS fusion panels in all new cases suggestive of sarcoma diagnosis in comparison with a use only indicated by a sarcoma-expert pathologist during the assessment. Therefore, although a significant proportion of sarcomas harbor specific molecular alterations, not all cases require NGS for a definitive diagnosis given that most sarcoma subtypes display classic histologic features. From a therapeutic perspective, current evidence does not support routine clinical use of NGS in all patients with sarcoma due to the small number of actionable alterations and the limited evidence for clinical benefit achieved with NGS-matched treatments. Although certain entities and molecular backgrounds demonstrate potential advantages, the consensus group emphasizes that indication of targeted agents for treatment is largely based on the specific subtype, and therefore, an accurate diagnosis is indispensable. CONCLUSIONS AND RELEVANCE: Evidence supporting the routine, nonselective use of NGS in patients with sarcoma is currently limited. Given the complexity, the decision to perform an NGS panel, as well as the interpretation and use of its results for diagnostic or therapeutic purposes, should take place only in sarcoma-expert institutions, including a multidisciplinary review. The results of multigene panels performed in nonexpert sarcoma centers cannot replace the pathology review or the recommendation of NGS-guided therapies without prior evaluation by sarcoma experts.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Serrano C, Bauer S, Blay JY, et al. Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review. JAMA Oncol. 2025. PMID: 41100097. doi:10.1001/jamaoncol.2025.3608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。